AP NEWS

Anti-CD37 Antibody Pipeline Insight, 2018 Report - ResearchAndMarkets.com

August 31, 2018

DUBLIN--(BUSINESS WIRE)--Aug 31, 2018--The “Anti-CD37 Antibody - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

‘Anti-CD37 Antibody - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD37 Antibody development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Anti-CD37 Antibody - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Anti-CD37 Antibody - Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Anti-CD37 Antibody

4. Comparative Analysis

5. Anti-CD37 Antibody Pipeline Products in Clinical Stages

Product Description Research and Development Product Development Activities

Other product profiles in the detailed report..

6. Anti-CD37 Antibody Pipeline Products in Non-clinical Stages

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Product Description Research and Development Product Development Activities Reason for dormancy/discontinuation

Companies Mentioned

Nordic Nanovector ImmunoGen Boehringer Ingelheim

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9c5w6m/anticd37?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180831005454/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/31/2018 03:19 PM/DISC: 08/31/2018 03:19 PM

http://www.businesswire.com/news/home/20180831005454/en

AP RADIO
Update hourly